Pharmaron Beijing (300759) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 reached ¥3.58 billion, up 15.48% year-over-year, with net profit attributable to shareholders rising 9.75% to ¥335 million.

• Adjusted net profit (non-IFRS) grew 16.25% year-over-year to ¥406 million.

• Laboratory services and CMC (small molecule CDMO) segments drove growth, with significant increases in new contract signings.

Financial highlights

• Operating cash flow was ¥604 million, down 29.13% year-over-year.

• Total assets at quarter-end were ¥28.56 billion, up 5.42% from year-end 2025.

• Shareholders’ equity increased 9.26% to ¥16.46 billion.

• Basic EPS was ¥0.1860, up from ¥0.1736 a year ago.

• Gross margin for laboratory services was 44.11%, CMC services 31.45%, and clinical research 7.10%.

Outlook and guidance

• New contract signings in Q1 2026 grew over 30% year-over-year, with laboratory services up 20% and CMC services up 50%.